Grèce Saba1, Luiz Flavio Andrade2, Jacques Gaillat3, Pierre Bonnin3, Christian Chidiac4, Hajnal-Gabriela Illes5, Henri Laurichesse5, Jonathan Messika6,7,8, Jean-Damien Ricard6,7,8, Bruno Detournay9, Patrick Petitpretz10, Gérard de Pouvourville11. 1. ESSEC Business School, Avenue Bernard Hirsch, 95021, Cergy-Pontoise Cedex, France. 2. ESSEC Business School, Avenue Bernard Hirsch, 95021, Cergy-Pontoise Cedex, France. andrade@essec.edu. 3. CH d'Annecy Genevois, Annecy, France. 4. Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France. 5. Hôpital Gabriel Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France. 6. AP-HP, Hôpital Louis Mourier, Service de Réanimation Médico-Chirurgicale, 178 rue des Renouillers, 92700, Colombes, France. 7. INSERM, IAME, UMR 1137, 75018, Paris, France. 8. Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, 75018, Paris, France. 9. CEMKA-EVAL, Bourg-la-Reine, France. 10. Hôpital André Mignot, Versailles, France. 11. ESSEC Business School, Avenue Bernard Hirsch, 95021, Cergy-Pontoise Cedex, France. pouvourville@essec.edu.
Abstract
OBJECTIVES: Pneumocost is a prospective study that aimed at documenting the costs of the management of patients hospitalized with a pneumococcal pneumonia and the post-discharge costs during a 6-month period in the French context. METHODS: Billing data were used to document hospital costs. Resource use during the follow-up period was collected through phone interviews at month 1, 3 and 6. Descriptive statistics and multivariate analyses were performed. We used generalized linear models with log-link functions to estimate parameters associated with hospital and follow-up costs of patients. RESULTS: Five hundred twenty-four patients were enrolled in 40 public centers from October 2011 to April 2014. Average age was 63 (SD 17); 55.0% of them were male. Average length of stay was 15 days (SD 23). Average cost of stay for the French Sickness Fund was €7293 (SD €7363). Average cost of follow-up was €1242 (SD €3000) and decreased steadily through time. When controlling for patient's socioeconomic characteristics, severity of disease and hospital stay, results showed a concave relationship between hospital costs and age. Obesity, the severity of the disease and comorbidities were associated with constantly increasing inpatient costs. Concerning follow-up costs, we found the same concave relationship with age, while gender, a history of pneumonia and severity of the disease were the most important predictors of high costs after discharge. CONCLUSION: Pneumocost is the first French study providing a robust estimation of the cost of managing invasive pneumococcal pneumonia in the French context.
OBJECTIVES: Pneumocost is a prospective study that aimed at documenting the costs of the management of patients hospitalized with a pneumococcal pneumonia and the post-discharge costs during a 6-month period in the French context. METHODS: Billing data were used to document hospital costs. Resource use during the follow-up period was collected through phone interviews at month 1, 3 and 6. Descriptive statistics and multivariate analyses were performed. We used generalized linear models with log-link functions to estimate parameters associated with hospital and follow-up costs of patients. RESULTS: Five hundred twenty-four patients were enrolled in 40 public centers from October 2011 to April 2014. Average age was 63 (SD 17); 55.0% of them were male. Average length of stay was 15 days (SD 23). Average cost of stay for the French Sickness Fund was €7293 (SD €7363). Average cost of follow-up was €1242 (SD €3000) and decreased steadily through time. When controlling for patient's socioeconomic characteristics, severity of disease and hospital stay, results showed a concave relationship between hospital costs and age. Obesity, the severity of the disease and comorbidities were associated with constantly increasing inpatient costs. Concerning follow-up costs, we found the same concave relationship with age, while gender, a history of pneumonia and severity of the disease were the most important predictors of high costs after discharge. CONCLUSION: Pneumocost is the first French study providing a robust estimation of the cost of managing invasive pneumococcal pneumonia in the French context.
Authors: Jose Bordon; Timothy Wiemken; Paula Peyrani; Maria Luz Paz; Martin Gnoni; Patricio Cabral; Maria del Carmen Venero; Julio Ramirez Journal: Chest Date: 2010-04-09 Impact factor: 9.410
Authors: A Ament; R Baltussen; G Duru; C Rigaud-Bully; D de Graeve; A Ortqvist; B Jönsson; J Verhaegen; J Gaillat; P Christie; A S Cifre; D Vivas; C Loiseau; D S Fedson Journal: Clin Infect Dis Date: 2000-09-05 Impact factor: 9.079
Authors: P Casez; J Fauconnier; L Jorgensen; E M Gutterman; S Gray; S Munson; N Dartois; J Gaillat Journal: Med Mal Infect Date: 2015-11-20 Impact factor: 2.152
Authors: Machaon M Bonafede; Jose A Suaya; Kathleen L Wilson; David M Mannino; Daniel Polsky Journal: Am J Manag Care Date: 2012-07 Impact factor: 2.229
Authors: Conrad E Vissink; Susanne M Huijts; G Ardine de Wit; Marc J M Bonten; Marie-Josée J Mangen Journal: BMC Infect Dis Date: 2016-09-02 Impact factor: 3.090
Authors: Luiz Flavio Andrade; Grèce Saba; Jean-Damien Ricard; Jonathan Messika; Jacques Gaillat; Pierre Bonnin; Christian Chidiac; Hajnal-Gabriela Illes; Henri Laurichesse; Bruno Detournay; Patrick Petitpretz; Gérard de Pouvourville Journal: Health Qual Life Outcomes Date: 2018-02-02 Impact factor: 3.186